Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Adverse events reported in published studiesa during or afterrituximab-induced B-cell depletion therapy

From: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study design

Infections Pneumoniab
  Shinglesb
  Thigh abscess, subcutaneous abscess
  Urinary tract infection
  Septicaemia
  Psuedomonas infection
  Staphyloccal abscess
  Streptococcal viridans infection
  Necrotising fasciitis
  Fatal histoplasmosis
Haematological Neutropeniab
Pulmonary Pneumonia
  Pulmonary haemorrhage
  Pulmonary embolism
  Respiratory failurec
  Breathlessness
Cardiac Cardiac failurec
  Fatal pancarditisc
  Pericarditis
  Tachycardia
Neurological Insomnia
  Transient ischaemic attack
Skin Localised or widespread rashb
  Pruritis
  Urticaria
Miscellaneous Infusion reactionsb
  Serum sickness reaction
  Hypogammaglobulinaemia
  Anaphylaxis
  Deep vein thrombosis
  Dyspepsia
  Malaise
  Pyrexia
  Polyarthralgia
  1. aSee Table 1. bFrequently reported adverse event.cLife-threatening complications.